1. INDICATIONS AND USAGE
1.1. Read these instructions carefully before use.
1.2. Rx ONLY.
1.3. Intended for the collection, processing and preservation of Whole Blood and blood components. Not intended for direct intravenous infusion.
1.4. For the collection of 500 mL ±10% Whole Blood.
1.5. Integral Diversion Blood Sampling Arm is intended to divert and obtain donor samples for laboratory testing prior to collection of the Whole Blood unit.
1.6. Integral filter unit intended for leukocyte reduction of Whole Blood up to 8 hours after blood collection when Whole Blood is stored at ambient temperature or cooled towards 1-10°C (transport temperature).
1.7. For further processing, use standard component processing techniques.

2. DOSAGE AND ADMINISTRATION
2.1. To open blister package, peel cover film back 4/5 of its length.
2.2. Prepare the blood bag following your institution's standard operating procedures.
2.2.1. Materials Needed:
   - VENOJECT®@ Tube Holder (code P-1316R) or equivalent
   - VENOJECT® Multi-Sample Luer Adapter (code MN2000T) or equivalent
   - Evacuated blood collection tubes (glass or plastic)

2.3. Make a loose knot in the donor tubing below the "Y" and CLIKTIP® (inline closure device) unless alternate methods are used to seal the tubing at the end of collection.
2.4. Temporarily clamp donor tubing between the phlebotomy needle and the "Y".
2.5. Close the White Clamp below the diversion pouch.
2.6. Assemble the luer adapter and the tube holder.
2.6.1. Connect the VENOJECT® Multi-Sample Luer Adapter to the VENOJECT® Tube Holder (or equivalent) (Fig. 1).

2.6.2. Twist and snap to remove the blue port cap at the end of the Diversion Blood Sampling Arm (Fig. 2a).

2.6.3. Insert the Holder/Luer assembly in the female luer port (Fig. 2b).

2.6.4. NOTE: Alternatively, steps 2.6.1., 2.6.2., and 2.6.3. (above) may be performed at any time during bag preparation or after the blood is collected into the diversion pouch.

2.7. Suspend the collection bag as far as possible below the donor's arm.

2.8. Apply blood pressure cuff or tourniquet to donor's arm. Disinfect site of phlebotomy. If blood pressure cuff is used, inflate to approximately 60 mmHg.

2.9. Remove the needle cover and perform phlebotomy. Remove the temporary clamp on the donor tubing to permit blood flow into the Diversion Blood Sampling Arm pouch.

2.9.1. CAUTION: Do not touch the needle after removing the needle cover.

2.9.2. CAUTION: Assure that the White Clamp below the pouch is closed prior to initiating phlebotomy.

2.10. Secure the needle safety device in place following the device instructions provided on the reverse side.

2.11. Secure donor tubing to donor's arm.

2.12. Position the diversion pouch with the notches up and the Tube Holder/Luer Adapter assembly (or port cap) down. When the level of blood in the pouch is approximately in line with the notches, the diversion pouch is full (Fig. 3a).

2.12.1. NOTE: The approximate fill volume of the pouch at the notches is 35 mL.

2.13. Permanently seal the tubing between the “Y” and the diversion pouch to maintain a closed system using an aluminum clip or a tube sealer approved for use with tubing connected to a donor (Fig. 3b).

2.13.1. CAUTION: Do not use a dielectric tube sealer to seal the tubing while the needle is connected to the donor's body unless it is approved for such a purpose.

2.14. To initiate blood flow into the collection bag, break the CLIKTIP between the “Y” and the collection bag.

2.15. To avoid clot formation, collect samples as soon as possible from the diversion pouch as follows (Fig. 3b).

2.15.1. CAUTION: Do not collect donor test samples until the tubing between the “Y” and the diversion pouch is permanently sealed.

2.15.2. Open the White Clamp on the tubing below the pouch to open the pathway for sampling.

2.15.3. Position the diversion pouch with the notches up and the Tube Holder/Luer Adapter assembly
downward. Assure that any air in the pouch is at the top and will not enter the blood collection tubes.

2.15.4. Insert blood collection tube firmly into the tube holder; when full, remove sample tube from holder. Repeat to collect additional samples.

2.15.5. **NOTE:** The pouch may be removed after the donor test samples are collected.

A second seal must be made between the diversion pouch and the permanent seal prior to removing the pouch.

2.16. Mix blood with anticoagulant in the collection bag and continue to mix at several intervals during collection and immediately after collection. If using an automated mixer, follow manufacturer's instructions.

2.17. Collect labeled volume of blood 500 mL ±10%.

2.18. When the desired amount of blood has been collected, seal the tubing or tighten the loose knot (white knot) prepared in Step 2.3. Make a second seal between the first seal or knot and the "Y". Various methods may be used to seal tubing.

2.19. Release pressure on the donor's arm and remove the needle into the needle safety device following the device instructions provided on the reverse side. Sever the donor tubing between the two seals previously made below the CLIKTIP and "Y".

2.19.1. **CAUTION:** Discard the Diversion Blood Sampling Arm and phlebotomy needle/donor tubing according to institutional standard operating procedures.

2.20. Seal and remove donor tubing from collection bag or strip donor tubing as follows:

2.20.1. To obtain a quality control prefiltration sample, strip blood from donor tubing into collection bag, mix well, and allow tubing to refill; repeat once. To prevent the blood from clotting in the tubing, work quickly as possible. Leave an adequate length of tubing containing the well-mixed anticoagulated whole blood attached to the collection bag.

2.20.2. Or, to maximize collection recovery, strip the tubing, mix well and seal tubing close to the collection bag without refilling. To prevent the blood from clotting in the tubing, work quickly as possible. Remove tubing from collection bag.

2.21. The blood filtration is executed according to the following operation. (see Fig.4)

2.21.1. **NOTE:** Red blood cells collected from certain donors may have extended filtration times and the potential for ineffective filtration and leukoreduction.

2.21.2. **NOTE:** Wait 30 minutes after collection before filtering. Filtration can be accomplished at room temperature for units maintained at room temperature and filtered within 8 hours of collection. Filtration can also be performed with units cooled towards 1-10°C within 8 hours of collection (e.g., during transport). If any unit has not completely filtered by 8 hours post collection, filtration must be completed at 1-6°C. Filtration can be unattended.
2.22. Mix the unfiltered whole blood unit by inverting the collection bag #1 (pre-filter bag) several times.

2.23. Hang the collection bag #1 and extend the filtration set to full length. Verify that the filter is vertical and ensure all tubing is freely suspended without kinks.

2.24. Break the CLIKTIP at the outlet of the collection bag #1.

2.24.1. The filter housing will begin to fill with blood and expand on the non-textured side.

2.24.2. Blood will flow across the filter pads and expand the textured side of the filter housing.

2.24.3. Air from the bag and filter will be forced into the primary bag #2 (post-filtration bag).

2.24.3.1. **CAUTION:** Do not squeeze or apply pressure on the filter while it is attached to the bag containing the filtered blood.

2.25. Filtration ends when the filter has emptied and the housing has collapsed onto the filter pads.

2.25.1. **NOTE:** Verify that collection bag #1 and pre-filtration tubing has emptied.

2.26. Gently squeeze the primary bag #2 to expel the air in the bag up the numbered segment tubing line and into the filter. To ensure ease of air removal ensure primary bag #2 is below the filter outlet.

2.27. Fill the numbered segment tubing with blood while expelling the air.

2.28. Clamp the blood filled tubing before blood enters the filter.

2.29. Seal the tubing as close as possible to the filter outlet and properly dispose of the filter and collection bag #1.

2.30. Strip the post filter tubing into the primary bag #2, mix well, and allow tubing to refill; repeat once. Make an appropriate number of segments of anticoagulated blood for testing by sealing on or near the X marks. Leave segments attached to the filtered whole blood unit.

2.31. The time between Whole Blood collection and component separation may vary depending on both the blood bag system and processing options selected.

2.31.1. **NOTE:** Production of Platelet concentrates is not intended with this product.

2.31.2. **NOTE:** Fresh Frozen Plasma should be separated from the Red Blood Cells and placed in a freezer at –18°C or colder within 8 hours of collection.

2.31.3. **NOTE:** OPTISOL should be added to the Red Blood Cells immediately after removal of the plasma. If plasma is not separated from the Red Blood Cells within 8 hours, OPTISOL may be added within 72 hours of collection if Whole Blood is refrigerated.

2.32. Follow your institution's standard component processing procedures to prepare components.

2.33. Centrifuge filtered whole blood unit to separate red cells from plasma.

2.34. Break the CLIKTIP of primary bag #2 and transfer leukocytes-reduced plasma into satellite bag
#3. Clamp transfer tubing of satellite bag.

2.35. Break the CLIKTIP of OPTISOL Solution bag #4 and drain contents into primary bag #2 containing red blood cells. Seal tubing of primary bag in two places, and cut between seals and separate from satellite bag(s).

2.35.1. **NOTE:** Empty OPTISOL container may be used for further component preparation.

2.36. Invert the red blood cell – OPTISOL mixture several times to assure the final product is well suspended.

2.37. Store AS-5 Red Blood Cells, Leukocytes Reduced between 1-6°C for up to 42 days.

2.37.1. **NOTE:** Whole Blood or Red Blood Cells in CPD may be stored for up to 21 days at 1-6°C.

3. **DOSAGE FORMS AND STRENGTHS**

3.1. 70 mL Citrate Phosphate Dextrose (CPD) anticoagulant USP for collection of 500 mL Whole Blood. Each 70 mL contains 1.79 g Dextrose (monohydrate) USP, 1.84 g Sodium Citrate (dihydrate) USP, 209 mg Citric Acid (anhydrous) USP, 156 mg Monobasic Sodium Phosphate (monohydrate) USP.

3.2. 111 mL OPTISOL Red Cell Preservative Solution. Each 111 mL contains 974 mg Sodium Chloride USP, 1.00g Dextrose (monohydrate) USP, 583 mg Mannitol USP, 33.3 mg Adenine USP.

5. **WARNINGS AND PRECAUTIONS**

5.1. Rx ONLY.

5.2. Do not use unless solutions are clear and free from particulates.

5.3. Always inspect the blood bag set for leaks before use.

5.4. Avoid excessive heat and direct sunlight. Protect from freezing.

5.5. Recommended storage conditions: Room Temperature (15-30°C/59-86°F).

5.6. It is normal to have condensation in the blister packaging. If the amount of moisture is greater than expected, check for leaks from the fluid-filled components of the blood bag set.

5.7. Use aseptic techniques.

5.8. Do not use a dielectric tube sealer to seal the tubing while the needle is connected to the donor's body unless it is approved for such a purpose.

5.9. Do not touch needle after removing the needle cover.

5.10. Assure that the White Clamp below the pouch is closed prior to initiating phlebotomy.

5.11. Do not collect donor test samples until the tubing between the "Y" and the diversion pouch is permanently sealed.

5.12. Discard the Diversion Blood Sampling Arm and phlebotomy needle/donor tubing according to institutional standard operating procedures.

5.13. The AGELESS® oxygen absorber packet, (Mitsubishi Gas Chemical) contained in this package absorbs oxygen and generates heat on removal. Do not open and handle it with care.

5.14. Dispose of the AGELESS packet with the blister tray.

5.15. Do not dispose the AGELESS packet with wastes containing volatile or flammable materials.

5.16. Due to possible exposure to infectious agents in the handling of blood, take adequate precautions at all times to prevent exposure to and transmission of such agents. Follow your institution's standard operating procedures.
11. DESCRIPTION / PRODUCT SPECIFICATIONS

11.1. This blood bag system includes a 16 gauge × 1 1/2 inch (1.60 × 38 mm) needle with needle cover and a 500mL (nominal capacity 600mL) collection bag containing 70mL Citrate Phosphate Dextrose (CPD) anticoagulant. The Quadruple blood bag set has one integrally attached empty primary bag, one empty satellite bag, and one satellite bag containing 111 mL OPTISOL Red Cell Preservative Solution.

11.2. Blood bag codes ending in A2 are the collection set with an Integral Diversion Blood Sampling Arm for obtaining donor samples prior to collection of the Whole Blood Unit. 11.3. Blood bag codes ending in A2 also include a DonorCare® Needle Guard pre-attached to the donor tubing. DonorCare Needle Guard device instructions are provided on the reverse side.

11.4. The blood bag collection set is made of PVC (polyvinyl chloride with DEHP plasticizer).

11.5. The blood bag has no components made of natural rubber latex.

11.6. Tubing internal diameter (ID) nominal 3.0 mm.

11.7. Tubing outer diameter (OD) nominal 4.4 mm.

11.8. Tubing line maximum 16 segments available.

16. HOW SUPPLIED/STORAGE AND HANDLING

16.1. Single use only.

16.2. Sterile and non-pyrogenic fluid path. Sterilized by steam. Opacity of the blood bag system may be observed. This is due to moisture absorption during the sterilization process. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

16.3. A Material Safety Data Sheet (MSDS) is not required for this product.

16.4. Recommended storage conditions: Room Temperature (15-30°C/59-86°F).

16.5. Avoid excessive heat and direct sunlight. Protect from freezing.

16.6. To open blister package, peel cover film back 4/5 of its length.

16.7. After opening the blister package, unused blood bags may be stored at room temperature for 96 hours or they may be stored for 30 days by returning cover film to original position and sealing with tape to prevent evaporation of solutions.

16.8. Blood bags in the unopened blister package may be used through the last day of the month and year as indicated on the original manufacturer's packaging.

16.9. The AGELESS packet contained in this package absorbs oxygen and generates heat on removal. Do not open and handle it with care.

16.10. Dispose of the AGELESS packet with the blister tray.

16.11. Do not dispose the AGELESS packet with wastes containing volatile or flammable materials.

16.12. For the Quadruple blood bag set, Code BBuWGQ506A2 is supplied 18/case.
PROCEDURE FOR USE OF DonorCare® Needle Guard

This device is for use by trained individuals.

Intended Use

The DonorCare® Needle Guard is incorporated onto the donor tubing to shield the needle immediately after withdrawal from the donor.

Single Use Only.

Preparation

1. Move the DonorCare on the tubing ensuring that it slides easily and the arrow is pointing toward the needle hub.

2. Ensure that the three lock points on the DonorCare are locked closed.

Whole Blood Collection

3. Perform the phlebotomy as per your institution's standard operating procedures.

4. Slide the DonorCare over the needle hub so that it covers approximately one half to two thirds of the needle hub.

5. Stabilize the DonorCare to the arm by placing a piece of tape over the front end so that the tape does not extend over the front of the DonorCare.

Withdrawal of Needle

Important

The DonorCare must be held stationary while the needle is withdrawn into it.

Caution

The needle must be fully shielded by DonorCare to prevent accidental injury.

6. Hold gauze over the venipuncture site with finger tips without exerting pressure. Hold the sides of the DonorCare near the front with the index finger and thumb of the same hand.
7. With the other hand, hold the donor tubing close behind the DonorCare.  
   **Note:** A hemostat may be placed on the tubing behind the DonorCare when the blood collection is complete.  
   This will help to prevent blood drops from forming.

8. Pull tubing smoothly and swiftly with one motion until the needle is locked in place inside the DonorCare.

9. Confirm that the needle is locked by:
   a. Listening for two 'clicks' as the needle is drawn into DonorCare.
   b. If the clicks are not heard as the needle is drawn into the DonorCare, continue to pull firmly on the tubing to assure needle is fully withdrawn into DonorCare.

10. Visually check that the needle is fully shielded by DonorCare before removing from the donor's arm.

11. Remove the tape from the DonorCare and arm.

12. Apply pressure to the gauze covering the venipuncture site.

   **Warning**
   Do not place fingers at the opening of DonorCare after removal from the donor's arm.

   **Difficult Phlebotomy** (Examples may include: Slow blood flow, deep or fine vein, steep angle)

   It may be necessary to delay placing the DonorCare over the needle hub until the end of the blood collection. In such situations:

   Leave the DonorCare on the tubing behind the needle hub. At the end of the blood collection carefully remove the tape from the needle hub and slide the DonorCare over the hub so that it covers approximately one half to two thirds of the needle hub. Withdraw the needle into the DonorCare as stated in steps 6. through 12. above.

   **Rx ONLY**

   DonorCare is manufactured by ITL Corporation, Melbourne, Australia.

   **TERUMO CORPORATION**

   44-1, 2-CHOME, HATAGAYA, SHIBUYA-KU,
   TOKYO 151-0072, JAPAN

   © TERUMO CORPORATION December, 2015
IMUFLEX® WB-RP BLOOD BAG SYSTEM WITH INTEGRAL WHOLE BLOOD LEUKOCYTE REDUCTION FILTER (REMOVING PLATELETS) WITH DIVERSION BLOOD SAMPLING ARM®

CPD WITH OPTISOL® RED CELL PRESERVATIVE SOLUTION FOR COLLECTION OF 500mL OF BLOOD

Each unit consists of a collection bag containing 70mL of Anticoagulant CPD solution, with a satellite bag containing 111mL of OPTISOL Red Cell Preservative Solution.
Each 70mL Anticoagulant CPD solution USP contains 1.79g Dextrose (monohydrate) USP, 1.84g Sodium Citrate (dihydrate) USP, 209mg Citric Acid (anhydrous) USP, 156mg Monobasic Sodium Phosphate (monohydrate) USP.
Each 111mL OPTISOL Red Cell Preservative Solution contains 974mg Sodium Chloride USP, 1.00g Dextrose (monohydrate) USP, 583mg Mannitol USP, 33.3mg Adenine USP.
STERILE, NON-PYROGENIC FLUID PATH.
DO NOT USE UNLESS ANTICOAGULANT IS CLEAR.

CODE
LOT No.
EXPIRY
UNITS
DONOR NEEDLE 16G × 1 1/2˝ (1.60 × 38mm)
Rx ONLY
RECOMMENDED STORAGE: Room Temperature (15-30°C/59-86°F).
Avoid excessive heat. Protect from freezing.

After opening, unused bags may be stored for 30 days by returning cover film to original position and sealing with tape to prevent possible loss of moisture.
See Instructions For Use.

Manufactured by: TERUMO CORPORATION Tokyo, Japan
® : Registered Trademark

Issued 01/06
B-4-HR6-A2 1
Place Label here
IMUFLEX WB-RP BLOOD BAG SYSTEM WITH INTEGRAL WHOLE BLOOD LEUKOCYTE REDUCTION FILTER (REMOVING PLATELETS) WITH DIVERISON BLOOD SAMPLING ARM ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) AND OPTISOL (AS-5) RED CELL PRESERVATIVE SOLUTION FOR COLLECTION OF 500mL OF BLOOD

Each unit consists of a collection bag containing 70mL of Anticoagulant CPD solution, with a satellite bag containing 111mL of OPTISOL Red Cell Preservative Solution.

Each 70mL Anticoagulant CPD solution USP contains 1.79g Dextrose (monohydrate) USP, 1.84g Sodium Citrate (dihydrate) USP, 209mg Citric Acid (anhydrous) USP, 156mg Monobasic Sodium Phosphate (monohydrate) USP.

Each 111mL OPTISOL Red Cell Preservative Solution contains 974mg Sodium Chloride USP, 1.00g Dextrose (monohydrate) USP, 583mg Mannitol USP, 33.3mg Adenine USP.

STERILE, NON-PYROGENIC FLUID PATH.
DO NOT USE UNLESS ANTICOAGULANT IS CLEAR.

CODE
LOT No.
EXPIRY

DONOR NEEDLE 16G×1½” (1.60×38mm)

Rx ONLY
RECOMMENDED STORAGE: Room Temperature (15-30 °C/ 59-86 °F).
Avoid excessive heat. Protect from freezing.

After opening, unused bags may be stored for 30 days by returning cover film to original position and sealing with tape to prevent possible loss of moisture.

See Instructions for Use.

TERUMO CORPORATION
Tokyo, Japan

Manufactured by

TERUMO REGISTERED TRADEMARK

Issued 01/98

B-4-HR3-A2 (C)
PRESERVATIVE
anticoagulant citrate phosphate dextrose (cpd) and as-5 red cell preservative kit

Product Information

Product Type | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:53877-006

Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:53877-006-31</td>
<td>18 in 1 CASE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>1 in 1 BAG</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Quantity of Parts

<table>
<thead>
<tr>
<th>Part #</th>
<th>Package Quantity</th>
<th>Total Product Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Part 1</td>
<td>1 BAG</td>
<td>70 mL</td>
</tr>
<tr>
<td>Part 2</td>
<td>1 BAG</td>
<td>111 mL</td>
</tr>
</tbody>
</table>

Part 1 of 2

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD)
anticoagulant citrate phosphate dextrose (cpd) solution

Product Information

Route of Administration | INTRAVENOUS

Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trisodium Citrate Dihydrate (UNII: B22547B95K) (Anhydrous Citric Acid - UNII:XF417D3PSL)</td>
<td>Anhydrous Citric Acid</td>
<td>26.3 g in 1000 mL</td>
</tr>
<tr>
<td>Sodium Phosphate, Monobasic, Unspecified form (UNII: 3980JH2SW) (Phosphate Ion - UNII:K80V8K8HR, Sodium Cation - UNII:LYR4M0NH37)</td>
<td>Sodium Phosphate, Monobasic, Unspecified form</td>
<td>2.22 g in 1000 mL</td>
</tr>
<tr>
<td>Dextrose Monohydrate (UNII: LX22YL083G) (Anhydrous Dextrose - UNII:5SL0G7R0OK)</td>
<td>Dextrose Monohydrate</td>
<td>25.5 g in 1000 mL</td>
</tr>
<tr>
<td>Anhydrous Citric Acid (UNII: XF417D3PSL) (Anhydrous Citric Acid - UNII:XF417D3PSL)</td>
<td>Anhydrous Citric Acid</td>
<td>2.99 g in 1000 mL</td>
</tr>
</tbody>
</table>

Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
</tbody>
</table>

Packaging

<table>
<thead>
<tr>
<th>Item</th>
<th>Marketing Start</th>
<th>Marketing End</th>
</tr>
</thead>
</table>
# Item Code | Package Description | Marketing Start Date | Marketing End Date
--- | --- | --- | ---
1 | 70 mL in 1 BAG; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product) | | 

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>BN880217</td>
<td>02/26/2010</td>
<td></td>
</tr>
</tbody>
</table>

### Part 2 of 2

**OPTISOL RED CELL PRESERVATIVE**
as-5 red cell preservative solution

### Product Information

**Route of Administration**

<table>
<thead>
<tr>
<th>Route of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTRAVENOUS</td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Chloride (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37)</td>
<td>Sodium Chloride</td>
<td>877 mg in 100 mL</td>
</tr>
<tr>
<td>Dextrose Monohydrate (UNII: LX22YL083G) (Anhydrous Dextrose - UNII:5SL0G7R0OK)</td>
<td>Dextrose Monohydrate</td>
<td>900 mg in 100 mL</td>
</tr>
<tr>
<td>Mannitol (UNII: 3OWL53L36A) (Mannitol - UNII:3OWL53L36A)</td>
<td>Mannitol</td>
<td>525 mg in 100 mL</td>
</tr>
<tr>
<td>Adenine (UNII: JAC85A2161) (Adenine - UNII:JAC85A2161)</td>
<td>Adenine</td>
<td>30 mg in 100 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>111 mL in 1 BAG; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>BN880217</td>
<td>02/26/2010</td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information
<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>BN880217</td>
<td>02/26/2010</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Terumo Corporation (690543319)

**Establishment**

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terumo Corp. - Fujinomiya Factory</td>
<td></td>
<td>695214015</td>
<td>MANUFACTURE(53877-006), STERILIZE(53877-006), ANALYSIS(53877-006), LABEL(53877-006)</td>
</tr>
</tbody>
</table>

Revised: 12/2019

Terumo Corporation